Public Relations (PR)
It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.
Weber Shandwick hired Susan Smirnoff away from the healthcare practice of Ruder Finn, where she had spent more than three decades.
The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
The drug maker says it has spoken to Deen about her racist comments, but an opaque company statement indicates the Danish firm has not cut ties with the now-former Food Network star.
Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.
GSK says 2013 will be a springboard for future growth, Burson-Marsteller hands out two new executive titles.
OraSure, the maker of the recently-approved home HIV test, has hired an experienced consumer marketer from Pfizer to head up the launch as it readies a TV ad campaign.
Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
The FDA has issued a rare untitled letter concerning a pitch letter - a reminder that the agency does not consider press materials to be exempted from its oversight.
The fan base of the AMA's publishing arm grew 115% in the second quarter.
The non-profit announced Thursday that it is on the hunt for a new president and two new board members, and that its beleaguered CEO will step down.
Roche shutters its Nutley, NJ, R&D site, and Porter Novelli names a new CEO.
An analysis of the FDA's handling of the Vytorin debacle points to a need for better public-health warnings about medications, researchers say.
A global study of consumer attitudes towards health found evidence for the "empowered consumer" hypothesis, with respondents expressing a greater sense of control over and responsibility for their health.
The most recent Johnson & Johnson recall may officially be CEO William Weldon's last. Alex Gorsky will become CEO as of April 26, the company said, and Weldon will stay on as chairman of the board of directors.
Despite recalls, a settlement over allegations of Medicare Fraud and illicit marketing of off-label drug use, a poll by research group Harris Interactive indicates that Johnson & Johnson's corporate reputation is dented, but intact.
Cowed by a fierce and lighting-quick backlash fueled by angry Tweets and Facebook posts, The Susan G. Komen for the Cure Foundation is backpedaling, but is it too late to reverse the reputation damage?
Johnson & Johnson is promoting the head of its global vision care business to serve as its marketing and PR chief, replacing global OTC chairman Brian Perkins, who is retiring, in that role.
Don't tell the New York Post, but Pfizer is boosting bike lanes as part of an Advil promotion.
Boehringer Ingelheim is hoping to create a new Facebook phenomenon with the development of a pharma civilization game that could give industry reputation a shot in the arm.
ProPublica's Dollars for Docs database has grown richer in pharma company payments but falls short in putting context around those expenditures, say industry-side critics.
Contrary to reports, hackers' brief takeover of the Pfizer Facebook page was probably not due to a security lapse by the social networking giant, security experts say.
Pfizer has usurped Merck as the most admired drug company among obstetricians and gynecologists, according to SDI's Pharmaceutical Company Image 2011 study, while Bayer increased its sales presence in that specialty significantly.
AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.
Porter Novelli named Susan Hayes global director of health, effective immediately.
Johnson & Johnson is reorganizing its troubled McNeil Consumer Healthcare unit in the US and installing new leadership.
Celebrities signing on as spokespeople for branded pharmaceuticals is nothing new, but now a generic drug supplier is getting in the game, with actor Eric Roberts serving as a kind of corporate celebrity ambassador.
An Abbott iPhone app is drawing attention to the practice of compensating bloggers for app reviews, as some call into question the ethics of pay-for-play online PR.
Pfizer awarded Ketchum a global assignment for Lipitor as the pharmaceutical company prepares for its top-selling drug to go off patent at the end of this year.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.